Adnay News Today

Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating)’s share price traded up 0.7% on Thursday . The stock traded as high as $2.92 and last traded at $2.88. 59,993 shares were traded during trading, an increase of 11% from the average session volume of 54,063 shares. The stock had previously closed at $2.86. Telesis Bio Price […]

Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating) dropped 8.4% during trading on Wednesday . The stock traded as low as $2.64 and last traded at $2.73. Approximately 66,821 shares traded hands during mid-day trading, an increase of 24% from the average daily volume of 54,063 shares. The stock had previously closed at $2.98. Telesis Bio […]

Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating) shares fell 4.2% on Tuesday . The stock traded as low as $2.51 and last traded at $2.76. 232,448 shares were traded during trading, an increase of 330% from the average session volume of 54,063 shares. The stock had previously closed at $2.88. Telesis Bio Trading Up 0.7 […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Codex DNA to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations. Institutional & Insider Ownership […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Codex DNA to related businesses based on the strength of its earnings, dividends, institutional ownership, profitability, risk, valuation and analyst recommendations. Profitability This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 43 public companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Codex DNA to similar companies based on the strength of its profitability, institutional ownership, valuation, dividends, risk, earnings and analyst recommendations. Profitability This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare Codex DNA to similar companies based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation. Institutional & Insider Ownership 87.6% of […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it compare to its competitors? We will compare Codex DNA to related companies based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership. Institutional & Insider Ownership 87.6% of […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Codex DNA to similar companies based on the strength of its valuation, analyst recommendations, profitability, risk, institutional ownership, dividends and earnings. Profitability This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Codex DNA Inc. is a creator of the BioXp(TM) system, a fully automated benchtop instrument which enables numerous synthetic biology workflows. Codex DNA Inc. […]